Gene Therapy Update for Friedreich’s Ataxia What patients and families should know (March 2026) Who is Lexeo Therapeutics? Lexeo Therapeutics is a biotechnology company developing gene therapies for heart disease, including heart involvement caused by Friedreich’s ataxia (FA)—a major cause of illness and premature death in FA. What treatment is...
The study is being conducted with multiple sites in the United States and Canada seeking to recruit approximately 9 participants aged 18-40 with a diagnosis of FA-associated cardiomyopathy. The study will be conducted by Dr. Antoine Duquette at the CHUM in Montreal. The choice of Montreal as a site reflects...
Following my last article, I will continue to tell you my story. Last time around, I talked about my childhood and mentioned what was “wrong” with me. Today you are going to find out what is “wrong” there. So here we go! For 11 months, I had all kinds of...
We are currently considering a new form of funding for Professor Tremblay’s project. Our goal is to develop a mouse model for the research on Friedreich’s Ataxia. The research project will soon be published in the American crowdfundig site CONSANO. Ataxia Canada will contribute equally to the amount collected. Access to...
NEWS RELEASE AmorChem, Université Laval and CHU de Québec collaborate on the development of a treatment for Friedreich’s Ataxia Montreal, August 4, 2014 – AmorChem, Université Laval and the CHU de Québec are happy to announce the start of a collaboration focusing on the discovery of a new treatment to...
In my opinion, the pursuit of one’s dreams is a big intrinsic motivation that we all need for self-fulfillment. My quest consists in participating in the 2012 London Paralympic Games. In fact, I am a high level swimmer and for four years I have had the deepest desire of accomplishing...
News Release Liestal, Switzerland, July 24, 2008 – Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/idebenone for the treatment of Friedreich’s Ataxia. Health Canada’s decision is the first marketing authorization worldwide for any Friedreich’s Ataxia therapy....